News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2017

Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon® 2.0 CE

PDF Liquid biopsy test delivers high sensitivity and specificity and may increase participation in cancer screening programs Berlin (Germany) and Germantown, MD (U.S.A.), February 14, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that an independent, peer-reviewed article on its blood-based colorectal cancer screening test Epi proColon 2.0 CE was published in the […]

Read more

Epigenomics AG: Systematic study review supports use of Epi proColon® in blood-based cancer detection

PDF Meta-analysis published in renowned journal “Clinical and Translational Gastroenterology” Berlin (Germany) and Germantown, MD (U.S.A.), January 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the scientific results of a recent systematic review and meta-analysis of clinical studies with Epi proColon were published in “Clinical and Translational Gastroenterology”, a journal of […]

Read more

Journal of “Cancer Treatment and Research Communications” Publishes Results of Study with Blood Test Epi proColon®

PDF ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer Screening Blood Test Compared to a Fecal Test Berlin (Germany) and Germantown, MD (U.S.A.), January 11, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the results of the ADMIT study have been published in the peer-reviewed journal Cancer Treatment and Research […]

Read more